Abstract
6580 Background: The Oncotype DX (Genomic Health, Redwood City, CA; GHI) RS estimates 10-yr risk of distant recurrence and CT benefit in patients (pts) with ER+, early-stage breast cancer (EBC). Af...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
